Greenwich LifeSciences, Inc.
GLSIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Greenwich LifeSciences, Inc. focuses on Biotechnology services and products. Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Valued at $233.4M, GLSI is a micro-cap name in its sector. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Market Cap
$233.4M
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
-19.39
EPS (TTM)
$-1.60
EPS (Fwd)
$-0.82
ROE
-986.3%
ROA
-236.0%
Cash
$8.9M
Total Debt
$0
Free CF
-$3.3M
52W Change
40.0%
Annual Financials
Cash vs Debt
Where GLSI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GLSI finished 30.23% below its 150-day moving average ($22.56) and 25.19% below its 200-day moving average ($21.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GLSI overbought or oversold?
At the September 3, 2026 close, GLSI's RSI(14) was 47.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Greenwich LifeSciences, Inc. reports $8.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$3.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -986.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GLSI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.